{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:32:27Z","timestamp":1781832747049,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuromyelitis optica spectrum disorder (NMOSD) often leads to disability and exerts a heavy toll on the work and life of affected female patients. This study aimed to analyze the current employment situation and economic burden as well as the risk factors for unemployment in female patients with NMSOD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We compared the following unemployment- and employment-related aspects in with NSMOD, which were investigated using questionnaires: the specific impact of NMOSD on work, medical expenses, and factors affecting unemployment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We enrolled 351 female patients with NMOSD. More than half (54.1%, 190\/351) of participants reported that the disease led to unemployment. The unemployment group was significantly older (46.9 \u00b1 12.1 years vs. 39.3 \u00b1 9.4 years, <jats:italic>P<\/jats:italic> = 0.000), had a higher annual recurrence rate (ARR) (0.6 [inter quartile range [IQR]:0.4\u20130.9] vs. 0.5 [IQR: 0.3\u20130.8], <jats:italic>P<\/jats:italic> = 0.141), and a higher severe disability rate (44.2% vs. 11.2%, <jats:italic>P<\/jats:italic> = 0.000) than the employment group. Moreover, unemployed patients had lower education levels. The factors influencing unemployment included low education (junior middle-school or below), age, higher ARR, and severe disability (odds ratio [OR] = 6.943, <jats:italic>P<\/jats:italic> = 0.000; OR = 1.034, <jats:italic>P<\/jats:italic> = 0.010; OR = 1.778, <jats:italic>P<\/jats:italic> = 0.038; and OR = 4.972, <jats:italic>P<\/jats:italic> = 0.000, respectively). Medication and hospitalization costs constituted the principal economic burdens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The heavy financial burden, employment difficulties, and high unemployment rate are the most prominent concerns of female patients with NMOSD who require more social support and concern.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.973163","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:18:25Z","timestamp":1662967105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Neuromyelitis optica spectrum disorder in Western China impacts employment and increases financial burden in women"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanLin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult Scler."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B5","volume-title":"Survey of Chinese Patients with Neuromyelitis Optica Spectrum Disorder","year":"2019"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.msard.2020.102542","article-title":"Neuromyelitis optica spectrum disorder in China: quality of life and medical care experience","volume":"46","author":"Huang","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","article-title":"Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression","volume":"293","author":"Shi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability statusscale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/acn3.51404","article-title":"Mortality of neuromyelitis optica spectrum disorders in a Chinese population","volume":"8","author":"Du","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.msard.2017.11.002","article-title":"Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina","volume":"19","author":"Fern\u00e1ndez","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/13696998.2021.1917421","article-title":"Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database","volume":"24","author":"Exuzides","year":"2021","journal-title":"J Med Econ."},{"key":"B13","first-page":"86","article-title":"A real-world analysis of relapses and costs of neuromyelitis optica spectrum disorders using a United States administrative claims database (P6.161)","author":"Stafkeymailey","year":"2016","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","article-title":"Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder","volume":"268","author":"Holm\u00f8y","year":"2021","journal-title":"J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms22062801","article-title":"Neuromyelitis optica spectrum disorder treatment-current and future Prospects","volume":"22","author":"Waliszewska-Pros\u00f3\u0142","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum Disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J Neuroimmunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4\u2013Positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hex.12432","article-title":"Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study","volume":"20","author":"Methley","year":"2017","journal-title":"Health Expect."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.973163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:18:30Z","timestamp":1662967110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.973163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":24,"alternative-id":["10.3389\/fneur.2022.973163"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.973163","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"973163"}}